請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90215完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 程藴菁 | zh_TW |
| dc.contributor.advisor | Yen-Ching Chen | en |
| dc.contributor.author | 蘇盈豪 | zh_TW |
| dc.contributor.author | Ying-Hao Su | en |
| dc.date.accessioned | 2023-09-22T17:53:26Z | - |
| dc.date.available | 2023-11-09 | - |
| dc.date.copyright | 2023-09-22 | - |
| dc.date.issued | 2023 | - |
| dc.date.submitted | 2023-08-09 | - |
| dc.identifier.citation | 1. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520-6.
2. Lin Y-C, Pan W-H. Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005-2008 (NAHSIT 2005-2008). Asia Pac J Clin Nutr. 2011;20(2):283-91. 3. Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR. Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population. Ann Pharmacother. 2021;55(7):821-9. 4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75. 5. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861-8. 6. Shieh A, Karlamangla AS, Huang MH, Han W, Greendale GA. Faster Lumbar Spine Bone Loss in Midlife Predicts Subsequent Fracture Independent of Starting Bone Mineral Density. J Clin Endocrinol Metab. 2021;106(7):e2491-e501. 7. Kröger H, Huopio J, Honkanen R, Tuppurainen M, Puntila E, Alhava E, et al. Prediction of fracture risk using axial bone mineral density in a perimenopausal population: a prospective study. J Bone Miner Res. 1995;10(2):302-6. 8. Holmberg A, Johnell O, Akesson K, Nilsson P, Nilsson JA, Berglund G. Forearm bone mineral density in 1294 middle-aged women: a strong predictor of fragility fractures. J Clin Densitom. 2004;7(4):419-23. 9. Crandall CJ, Hovey KM, Cauley JA, Andrews CA, Curtis JR, Wactawski-Wende J, et al. Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study. J Bone Miner Res. 2015;30(11):2086-95. 10. Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 2016;27(4):1281-386. 11. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc. 2011;86(1):50-60. 12. Kuchuk NO, Pluijm SM, van Schoor NM, Looman CW, Smit JH, Lips P. Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab. 2009;94(4):1244-50. 13. Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V. The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol. 2010;79(1):1-9. 14. van Schoor NM, Visser M, Pluijm SM, Kuchuk N, Smit JH, Lips P. Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone. 2008;42(2):260-6. 15. Adami S, Bertoldo F, Braga V, Fracassi E, Gatti D, Gandolini G, et al. 25-hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone. 2009;45(3):423-6. 16. Ardawi MS, Qari MH, Rouzi AA, Maimani AA, Raddadi RM. Vitamin D status in relation to obesity, bone mineral density, bone turnover markers and vitamin D receptor genotypes in healthy Saudi pre- and postmenopausal women. Osteoporos Int. 2011;22(2):463-75. 17. Zhen D, Liu L, Guan C, Zhao N, Tang X. High prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factors. Bone. 2015;71:1-6. 18. Saadeh R, Jumaa D, Elsalem L, Batieha A, Jaddou H, Khader Y, et al. Osteoporosis among Postmenopausal Women in Jordan: A National Cross-Sectional Study. Int J Environ Res Public Health. 2022;19(14). 19. Tsai KS, Hsu SH, Cheng JP, Yang RS. Vitamin D stores of urban women in Taipei: effect on bone density and bone turnover, and seasonal variation. Bone. 1997;20(4):371-4. 20. Reinholt FP, Hultenby K, Oldberg A, Heinegård D. Osteopontin--a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 1990;87(12):4473-5. 21. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA. 1999;96(14):8156-60. 22. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, et al. Resistance to unloading‐induced three‐dimensional bone loss in osteopontin‐deficient mice. J Bone Miner Res. 2002;17(4):661-7. 23. Richards JB, Kavvoura FK, Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med. 2009;151(8):528-37. 24. Chen JH, Chen YC, Mao CL, Chiou JM, Tsao CK, Tsai KS. Association between secreted phosphoprotein-1 (SPP1) polymorphisms and low bone mineral density in women. PLoS One. 2014;9(5):e97428. 25. Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone. 2007;40(6):1517-28. 26. van der Meijden K, Lips P, van Driel M, Heijboer AC, Schulten EA, den Heijer M, et al. Primary human osteoblasts in response to 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3. PLoS One. 2014;9(10):e110283. 27. Nsengiyumva V, Krishna SM, Moran CS, Moxon JV, Morton SK, Clarke MW, et al. Vitamin D deficiency promotes large rupture-prone abdominal aortic aneurysms and cholecalciferol supplementation limits progression of aneurysms in a mouse model. Clin Sci (Lond). 2020;134(18):2521-34. 28. Enkhjargal B, McBride DW, Manaenko A, Reis C, Sakai Y, Tang J, et al. Intranasal administration of vitamin D attenuates blood-brain barrier disruption through endogenous upregulation of osteopontin and activation of CD44/P-gp glycosylation signaling after subarachnoid hemorrhage in rats. J Cereb Blood Flow Metab. 2017;37(7):2555-66. 29. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012;82(12):1261-70. 30. Cauley JA, Chalhoub D, Kassem AM, Fuleihan Gel H. Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol. 2014;10(6):338-51. 31. Shao CJ, Hsieh YH, Tsai CH, Lai KA. A nationwide seven-year trend of hip fractures in the elderly population of Taiwan. Bone. 2009;44(1):125-9. 32. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol. 2021;9(12):837-46. 33. Zhou A, Selvanayagam JB, Hyppönen E. Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk. Eur Heart J. 2022;43(18):1731-9. 34. Michaëlsson K, Wolk A, Byberg L, Mitchell A, Mallmin H, Melhus H. The seasonal importance of serum 25-hydroxyvitamin D for bone mineral density in older women. J Intern Med. 2017;281(2):167-78. 35. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008;43(6):1115-21. 36. Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74(11):1498-513. 37. Lin JD, Chiou WK, Weng HF, Fang JT, Liu TH. Application of three-dimensional body scanner: observation of prevalence of metabolic syndrome. Clin Nutr. 2004;23(6):1313-23. 38. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12. 39. Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305(17):1790-9. 40. Feng YA, Chen CY, Chen TT, Kuo PH, Hsu YH, Yang HI, et al. Taiwan Biobank: A rich biomedical research database of the Taiwanese population. Cell Genom. 2022;2(11):100197. 41. Wray NR. Allele frequencies and the r2 measure of linkage disequilibrium: impact on design and interpretation of association studies. Twin Res Hum Genet. 2005;8(2):87-94. 42. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet. 1995;56(3):799-810. 43. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-5. 44. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928-9. 45. Shin J-H, Blay S, McNeney B, Graham J. LDheatmap: an R function for graphical display of pairwise linkage disequilibria between single nucleotide polymorphisms. J Stat Softw. 2006;16:1-9. 46. Moore CM, Jacobson SA, Fingerlin TE. Power and Sample Size Calculations for Genetic Association Studies in the Presence of Genetic Model Misspecification. Hum Hered. 2019;84(6):256-71. 47. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477-501. 48. Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25(4):585-91. 49. LeBoff MS, Chou SH, Murata EM, Donlon CM, Cook NR, Mora S, et al. Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL). J Bone Miner Res. 2020;35(5):883-93. 50. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet. 2014;383(9912):146-55. 51. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-11. 52. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920-8. 53. Taylor BC, Schreiner PJ, Doherty TM, Fornage M, Carr JJ, Sidney S. Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. Hum Genet. 2005;116(6):525-8. 54. Souza VC, Freitas WM, Quaglia LA, Santos SN, Córdova C, Sposito AC, et al. Osteopontin in bone mineral density of very old Brazilians. J Bone Miner Metab. 2013;31(4):449-54. 55. Jiang Z, Pu R, Li N, Chen C, Li J, Dai W, et al. High prevalence of vitamin D deficiency in Asia: A systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2021:1-10. 56. Darling AL. Vitamin D deficiency in western dwelling South Asian populations: an unrecognised epidemic. Proc Nutr Soc. 2020;79(3):259-71. 57. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010;85(8):752-7; quiz 7-8. 58. Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(14):1436-42. 59. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat Genet. 2019;51(2):258-66. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90215 | - |
| dc.description.abstract | 目標：
本研究目的在檢驗以下兩點：1）25-羥基膽鈣化醇濃度與骨密度之間的線性和非線性關聯性；以及2）SPP1（secreted phosphoprotein 1）基因多態性與維生素D缺乏對骨密度的聯合影響。 方法： 此橫斷面研究共招募了657名中年女性，其中包括524名停經前及133位停經後。利用雙能量X光吸光式測定儀測量了腰椎的面積性骨密度（g/cm2）。我們從SPP1基因中選擇了三個標記SNP作分析（rs11730582來自啟動子，rs6839524來自外顯子，rs4754來自內含子）。我們用不同方法評估了25-羥基膽鈣化醇對骨密度的影響，作為連續變項、序列變項（三分等級）或二元變項（維生素D缺乏，臨界值25-羥基膽鈣化醇 <20 ng/mL）指標。根據女性的更年期狀態，低骨密度的定義有所不同。在停經前女性中，以Z分數(Z-score)落在最低四分位數內定義為低骨密度。相反，在停經後女性中，低骨密度定義包括帶有骨質稀少(osteopenia)或骨質疏鬆症(osteoporosis)。 結果： 中年女性併維生素D缺乏會增加低骨密度風險（調整過的勝算比在停經前女性為1.65，95%信賴區間為1.06-2.61；停經後女性其調整過的勝算比3.04，95%信賴區間為1.08-9.36），在調整了年齡、BMI (body mass index)、體脂肪、測量維生素D的季節、體力活動、鈣質補充和久坐工作後。多項式回歸分析顯示25-羥基膽鈣化醇的二次項為顯著，在停經前和停經後婦女中，25-羥基膽鈣化醇濃度與低骨密度風險之間呈倒J型關係。停經後且維生素D充足的女性，若攜帶rs11730582 變異體或者包含等位基因的 CCT 單倍體，則會有減少的低骨密度風險；然而，停經後女性併維生素D缺乏且攜帶 rs6839524 變異體，或者攜帶 rs4754 野生型基因，則有上升的低骨密度風險。 結論： 我們的結果表示，充足的維生素D濃度在中年女性的骨質健康扮演角色。且維他命D濃度與低骨密度風險間有非線性關係。停經後女性較易受到SPP1基因多態性和維生素D缺乏的聯合影響。 | zh_TW |
| dc.description.abstract | Objectives: The study aimed to investigate the followings: 1) the association of 25-hydroxycholecalciferol levels with bone mineral density (BMD) using linear and nonlinear analyses, and 2) the joint effect of secreted phosphoprotein 1 (SPP1) genetic polymorphisms and vitamin D deficiency on BMD.
Materials and methods: A total of 657 women, including 524 premenopausal and 133 postmenopausal individuals, were enrolled. Areal BMD (g/cm2) of the lumbar spine was measured by dual-energy X-ray absorptiometry. Three tagging single nucleotides polymorphisms (SNPs) from promotor (rs11730582), exon (rs6839524), and intron (rs4754) were selected from the SPP1 gene. The effect of 25-hydroxycholecalciferol on BMD was assessed as a continuous, ordinal (tertile), or dichotomous (vitamin D deficiency with a cut-off value of 25-hydroxycholecalciferol < 20 ng/mL) indicator. Low BMD was characterized differently depending on the menopausal status of the women. In premenopausal women, it was determined by a Z-score that fell within the lowest quartile. Conversely, in postmenopausal women, the definition included the presence of osteopenia or osteoporosis. Results: A significant association of vitamin D deficiency with the risk of low BMD was observed in premenopausal (adjusted odds ratio [aOR]: 1.65, 95% confidence interval [CI]: 1.06-2.61) and postmenopausal women (aOR: 3.04, 95% CI 1.08-9.36), after adjustments for age, body mass index, body fat percentages, seasons of blood collection, physical activity, calcium supplementations, and sedentary work. Nonlinear, polynomial regression analyses indicated that the quadratic term of 25-hydroxycholecalciferol levels was significant and a reverse J-shaped relationship between 25-hydroxycholecalciferol levels and the risk of low BMD in midlife women was found. Postmenopausal, vitamin D-repleted women who carry rs11730582 variant or the haplotype CCT have a reduced risk of low BMD, while vitamin D-deficient, postmenopausal women carrying rs6839524 variant or rs4754 wild type have an elevated risk of low BMD. Conclusion: Adequate vitamin D levels play a role in bone health in midlife women. A nonlinear association of 25-hydroxycholecalciferol levels with the risk of low BMD was observed. Postmenopausal women may be susceptible to the joint effect of vitamin D deficiency and SPP1 genetic polymorphisms. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-22T17:53:26Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2023-09-22T17:53:26Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 v 目錄 vii 圖目錄 ix 表目錄 x 1. Introduction 1 1.1 Osteoporosis 1 1.2 Vitamin D 1 1.3 Effects of SPP1 genetic polymorphisms on BMD 2 1.4 Research gaps and study aims 2 2. Materials and Methods 4 2.1 Study design and population 4 2.2 Assessment of BMD 4 2.3 Assessment of vitamin D level and covariates 5 2.4 Genotyping 5 2.5 Statistical analyses 6 3. Results 8 3.1 Descriptive statistics 8 3.2 Vitamin D effect by logistic regression analysis 8 3.3 Vitamin D effect by nonlinear regression analysis 9 3.4 The joint effect of vitamin D deficiency and SPP1 genetic polymorphism 9 3.5 Post-hoc power analyses and Comparison of model fits 10 4. Results 11 4.1 Main findings 11 4.2 Postulated Mechanism 11 4.3 Comparison with previous studies 12 4.4 Strengths of this study 14 4.5 Limitations of this study 14 4.6 Clinical implications 15 5. Conclusion 16 References 17 | - |
| dc.language.iso | en | - |
| dc.subject | 骨橋蛋白 | zh_TW |
| dc.subject | 維他命D | zh_TW |
| dc.subject | 骨質稀少 | zh_TW |
| dc.subject | 單核苷多樣性 | zh_TW |
| dc.subject | 骨質密度 | zh_TW |
| dc.subject | 骨質疏鬆 | zh_TW |
| dc.subject | 分泌磷蛋白1 | zh_TW |
| dc.subject | osteopenia | en |
| dc.subject | vitamin D | en |
| dc.subject | bone mineral density | en |
| dc.subject | osteopontin | en |
| dc.subject | secreted phosphoprotein 1 | en |
| dc.subject | single nucleotide polymorphisms | en |
| dc.subject | osteoporosis | en |
| dc.title | 維生素D 缺乏症和SPP1（骨橋蛋白）遺傳多態性與 中年女性骨密度的相互關係。橫斷面研究 | zh_TW |
| dc.title | The intercorrelation of vitamin D deficiency and SPP1 (Osteopontin) genetic polymorphisms with bone mineral density in middle-aged women. A cross-sectional study | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 111-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 蔡克嵩;陳人豪;馮嬿臻 | zh_TW |
| dc.contributor.oralexamcommittee | Keh-Sung Tsai;Jen-Hau Chen;Yen-Chen Anne Feng | en |
| dc.subject.keyword | 維他命D,骨質密度,骨橋蛋白,分泌磷蛋白1,單核苷多樣性,骨質疏鬆,骨質稀少, | zh_TW |
| dc.subject.keyword | vitamin D,bone mineral density,osteopontin,secreted phosphoprotein 1,single nucleotide polymorphisms,osteoporosis,osteopenia, | en |
| dc.relation.page | 35 | - |
| dc.identifier.doi | 10.6342/NTU202303591 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2023-08-09 | - |
| dc.contributor.author-college | 公共衛生學院 | - |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-111-2.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 2.17 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。